Exploring the effect of patient characteristics on the association between warm ischemia time and the risk of postoperative acute kidney injury after partial nephrectomy

May 11, 2025 by in ONCOLOGY Comments Off on Exploring the effect of patient characteristics on the association between warm ischemia time and the risk of postoperative acute kidney injury after partial nephrectomy

Highlights • Patients undergoing partial nephrectomy with multiple comorbidities face a higher risk of postoperative acute kidney injury (AKI). • The risk of AKI escalates with increased warm ischemia time,…

read more

A noninvasive comprehensive model based on medium sample size had good diagnostic performance in distinguishing renal fat-poor angiomyolipoma from homogeneous clear cell renal cell carcinoma

May 11, 2025 by in ONCOLOGY Comments Off on A noninvasive comprehensive model based on medium sample size had good diagnostic performance in distinguishing renal fat-poor angiomyolipoma from homogeneous clear cell renal cell carcinoma

Highlights • It is difficult to distinguish fp-AML and hm-ccRCC using conventional imaging methods. • Whole-tumor histogram analysis can serve as a powerful mean to distinguish fp-AML and hm-ccRCC. •…

read more

Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157)

May 11, 2025 by in ONCOLOGY Comments Off on Delayed partial nephrectomy following complete response to immunotherapy: feasibility and results (UroCCR n°157)

Highlights • Nephron-sparing surgeries after response to immunotherapy are feasible. • These surgeries offer prolonged remissions and good functional results. • These surgeries can be performed with limited morbidity. •…

read more

Immediate second resection versus restage transurethral resection of bladder tumor: A prospective randomized clinical trial (IMMERSE trial)

May 11, 2025 by in ONCOLOGY Comments Off on Immediate second resection versus restage transurethral resection of bladder tumor: A prospective randomized clinical trial (IMMERSE trial)

Highlights • Detrusor muscle sampling rates are significantly higher in patients undergoing immediate second resection than standard TURBT (97% vs. 66%). • There is a high rate of recurrence in…

read more

The clinical relevance of cut-off percentage for high-grade urothelial carcinoma within low-grade urothelial carcinoma: A determining factor?

May 11, 2025 by in ONCOLOGY Comments Off on The clinical relevance of cut-off percentage for high-grade urothelial carcinoma within low-grade urothelial carcinoma: A determining factor?

Abstract Aims The aim of the study was to analyze the cut-off value for the percentage of the high-grade (HG) component that has clinical significance in urothelial carcinoma (UC). Material…

read more

Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer

May 11, 2025 by in ONCOLOGY Comments Off on Tumor location at trans-urethral resection is predictive of ipsilateral pelvic lymph-nodal metastases in patients undergoing radical cystectomy for bladder cancer

Highlights • Tumor location at TURBT predicts ipsilateral lymph node metastases. • Right-sided tumors show more positive ipsilateral lymph nodes. • Left-sided tumors also predict increased ipsilateral node positivity. •…

read more

Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma

May 11, 2025 by in ONCOLOGY Comments Off on Pattern and risk factors of local recurrence and intravesical recurrence after segmental ureterectomy for upper tract urothelial carcinoma

Highlights • Segmental ureterectomy was feasible for selected ureteral cancer patients. • Segmental ureterectomy faced a considerable risk of local recurrence and intravesical recurrence. • G3 and lymphatic vascular infiltration…

read more

Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan

May 11, 2025 by in ONCOLOGY Comments Off on Real-world treatment patterns and outcomes of patients with unresectable or metastatic urothelial carcinoma receiving systemic therapy in Japan

Highlights • A study in patients with unresectable or metastatic urothelial carcinoma (mUC). • Half of patients received cisplatin-based regimens as first-line therapy. • After 2017, 58.2% of patients received…

read more
Get Clinical Tree app for offline access